Stocktoria
Lyra Therapeutics, Inc. LYRA
OTC · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2020-05-01
Lyra Therapeutics, Inc. (LYRA) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $398,000 at a -7266.1% net margin.
2/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Price from month-end closes (Yahoo) — for reference, not real-time.
Market cap$1M
Net margin-7266.1%
Revenue trend · last 5y · up
How it ranks in Manufacturing · percentile among 1906 companies
Piotroski Fstronger than 12%
Net marginstronger than 4%
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| LYRA | Lyra Therapeutics, Inc. | 2/9 | — | — | — |
| PLSE | PULSE BIOSCIENCES, INC. | 2/9 | -10.11 | — | — |
| QTEX | QTREX Quantum Ltd. | 2/9 | — | — | — |
| FOFA | FAMILY OFFICE OF AMERICA, INC. | 2/9 | -13.31 | — | — |
| SKYA | SkyAI, Inc. | 3/9 | — | — | — |
| CODX | Co-Diagnostics, Inc. | 1/9 | -16.26 | — | — |
| PAVM | PAVmed Inc. | 3/9 | — | 90.2 | — |
FAQ
Is LYRA financially healthy?
Lyra Therapeutics, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does LYRA pay a dividend?
No, Lyra Therapeutics, Inc. does not currently pay a dividend.
How profitable is LYRA?
In FY2025, Lyra Therapeutics, Inc. had a net margin of -7266.1%.
Source: SEC EDGAR filings · CIK 0001327273 · US · as of 2025-12-31. facts plus Stocktoria's own computed scores — not investment advice.